StimOxyGen

Executive Summary

StimOxyGen is a UK-based nanotechnology company focused on addressing tumor hypoxia, a critical unmet need in oncology. Hypoxia in solid tumors enhances cancer cell survival and reduces the efficacy of standard therapies including radiotherapy, certain chemotherapies, and emerging oxygen-dependent sensitiser approaches. Founded in 2017 and headquartered in London, the company aims to develop innovative solutions to overcome this barrier, potentially improving treatment outcomes across multiple cancer types. While financial details and clinical stage are not publicly disclosed, StimOxyGen's positioning in the nanotech space suggests a platform technology that could be broadly applicable.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first-in-human Phase I trial20% success
• Q2 2026Presentation of preclinical efficacy data at major oncology conference40% success
• Q3 2026Strategic partnership or licensing deal with larger pharma15% success